Home > Healthcare > Analytical Instruments > Elemental Analysis > Label-free Array Systems Market

Label-free Array Systems Market Trends

  • Report ID: GMI9649
  • Published Date: May 2024
  • Report Format: PDF

Label-free Array Systems Market Trends

The rising cases of chronic and infectious diseases is a significant driver for market. With increasing incidences of chronic and infectious diseases, there is a heightened demand for advanced diagnostic tools that can provide rapid, accurate, and real-time detection of biomarkers associated with these diseases.

  • According to the World Health Organization (WHO), in 2024, over 35 million new cancer cases are predicted in 2050, a 77% increase from the 20 million cases in 2022.
  • Similarly, as per the same report, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
  • The surge in chronic and infectious diseases necessitates the development of new therapeutics. Label-free array systems are essential in the drug discovery process, as they enable detailed analysis of biomolecular interactions, helping researchers identify and develop effective drugs more efficiently.
  • Chronic diseases such as cancer, diabetes, and cardiovascular diseases, often require personalized treatment approaches. Label-free array systems facilitate the study of individual patient samples to identify specific biomarkers and tailor treatments, thereby increasing the growth of the market.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global label-free array systems industry size was valued at USD 1.4 billion in 2023 and is estimated to grow at 7.2% CAGR from 2024 to 2032 due to increasing drug discovery and development activities and rising cases of chronic and infectious diseases.

The surface plasmon resonance (SRP) segment in the market is estimated to account for USD 669.2 million by 2032 because SRP technology offers sensitive and label-free detection of biomolecular interactions.

The drug discovery segment of the label-free array systems market accounted for USD 483.6 million in 2023 due to screening large libraries of compounds to identify potential drug candidates and the ability to conduct real-time analysis.

Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Merck KGaA, Meso Scale Diagnostics (MSD), Nanion Technologies, and Pall Corporation, among others.

Label-free Array Systems Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 237
  • Countries covered: 23
  • Pages: 150
 Download Free Sample